BGM Group Ltd. (BGM)
BGM trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-09-30, https://www.sec.gov/Archives/edgar/data/1779578/000110465926085247/0001104659-26-085247-index.htm. Net income: SEC 20-F (us-gaap:NetIncomeLoss), fiscal year ended 2025-09-30.
Profile
| Field | Value |
|---|---|
| Ticker | BGM on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | China |
| IPO year | 2021 |
| SEC CIK | 0001779578 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Cayman Islands |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $37.9M |
| Net income | -$19.9M |
| Operating income | -$12.6M |
| Net margin | -52.6% |
| Operating margin | -33.2% |
| Revenue growth | +51.1% |
| Cash | $9.8M |
| Total assets | $433.8M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 2.8× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 20-F 2026-07-21 |
| Cash and burn | $9.8M cash; operating cash flow -$593K a quarter. | Report 2025-09-30 |
| Shares outstanding | 13,374,891 (2025-09-30); 14,452,960 a year earlier. the newest SEC cover-page count is from 2025-09-30; shares issued since then are not in these figures. | Cover page 2025-09-30 |
| Reverse splits, 3 years | 2; latest 1-for-30 on 2026-10-01 | Source 2026-10-01 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | ENROME LLP, Singapore, Singapore | PCAOB Form AP 2026-07-29 |
| Late filings, 12 months | 1 NT notice | NT 20-F 2026-01-30 |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-09-30 | $37.9M | -$19.9M | -$2.4M | $9.8M | No debt tags | $37.9M | 20-F 2026-07-21 |
| FY 2024 2024-09-30 | $25.1M | -$1.4M | $544K | $9.8M | No debt tags | $25.1M | 20-F 2026-07-21 |
| FY 2023 2023-09-30 | $46.5M | -$7.8M | $312K | $7.5M | No debt tags | $46.5M | 20-F 2026-07-21 |
| FY 2022 2022-09-30 | $64.9M | $1.1M | $12.7M | $14.3M | No debt tags | $64.9M | 20-F/A 2025-04-03 |
| FY 2021 2021-09-30 | $57.1M | $3.2M | $345K | $10.5M | No debt tags | $57.1M | 20-F 2024-02-15 |
| FY 2020 2020-09-30 | $50.0M | $5.1M | $5.1M | $11.9M | No debt tags | $50.0M | 20-F 2023-04-19 |
| FY 2019 2019-09-30 | $46.1M | $5.9M | -$580K | $4.6M | No debt tags | $46.1M | 20-F/A 2022-10-13 |
| FY 2018 2018-09-30 | $50.4M | $5.2M | $4.4M | $5.6M | No debt tags | $50.4M | 20-F/A 2021-03-09 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document FORM F-3 | F-3 | 2025-03-07 |
| Latest annual report | 20-F | 2026-07-21 |
| Latest quarterly / interim FORM 6-K | 6-K | 2026-09-24 |
Source: SEC EDGAR submissions feed, 154 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -4.5% |
| 1 month | -24.9% |
| 3 months | -12.2% |
| Year to date | -92.9% |
| 1 year | -97.1% |
| From 52-week high | -97.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| FHTX | Foghorn Therapeutics Inc. | $1.79 | -13.53% | $107.3M |
| ADAG | Adagene Inc. | $1.60 | -6.43% | $105.7M |
| CLLS | Cellectis S.A. | $1.04 | -11.86% | $104.5M |
| DERM | Journey Medical Corporation | $3.70 | -14.55% | $104.5M |
| NERV | Minerva Neurosciences Inc | $2.20 | -4.35% | $109.6M |
| ORGO | Organogenesis Holdings Inc. | $0.8031 | -0.86% | $104.2M |
| UNCY | Unicycive Therapeutics Inc. | $3.70 | +4.23% | $103.1M |
| OKUR | OnKure Therapeutics Inc. | $2.75 | +4.56% | $111.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier